Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0278
-0.0002 (-0.71%)
Aug 6, 2026, 1:02 PM EST
Adaptimmune Therapeutics Revenue
In the year 2025, Adaptimmune Therapeutics had annual revenue of $5.92M. Adaptimmune Therapeutics had revenue of $-7.52M in the quarter ending December 31, 2025.
Revenue
5.92M
Revenue Growth
-95.58%
P/S Ratio
1.23
Revenue / Employee
21.78K
Employees
272
Market Cap
7.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.92M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 60.28M | 33.13M | 122.05% |
| Dec 31, 2022 | 27.15M | 21.00M | 341.50% |
| Dec 31, 2021 | 6.15M | 2.19M | 55.36% |
| Dec 31, 2020 | 3.96M | 2.84M | 252.76% |
| Dec 31, 2019 | 1.12M | -58.38M | -98.11% |
| Dec 31, 2018 | 59.51M | 21.67M | 57.28% |
| Dec 31, 2017 | 37.83M | 23.64M | 166.47% |
| Dec 31, 2016 | 14.20M | 5.22M | 58.12% |
| Dec 31, 2015 | 8.98M | -892.00K | -9.04% |
| Jun 30, 2015 | 9.87M | 9.05M | 1,096.48% |
| Jun 30, 2014 | 825.00K | - | - |
| Jun 30, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Adaptimmune Therapeutics News
- 9 months ago - Adaptimmune Announces Changes to Board and Executive Leadership Team - Newsfile Corp
- 10 months ago - Adaptimmune Announces Delisting from Nasdaq - Newsfile Corp
- 1 year ago - Adaptimmune Reports Q2 Financial Results and Provides Business Update - Newsfile Corp
- 1 year ago - Adaptimmune Therapeutics Quarterly report: Q2 2025 - Filings
- 1 year ago - Adaptimmune Therapeutics Earnings release: Q2 2025 - Filings
- 1 year ago - Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds - Newsfile Corp
- 1 year ago - Adaptimmune Therapeutics Earnings Call Transcript: Q1 2025 - Transcripts
- 1 year ago - Adaptimmune Therapeutics Quarterly report: Q1 2025 - Filings